Inside the Landmark Sanofi–Vicebio Acquisition: Insights and Lessons from UniQuest’s Commercialisation Team
Go behind the scenes of the largest deal in the history of Australian university commercialisation and discover how UQ’s Molecular Clamp technology is poised to make a global health impact. Hear insights from the UniQuest team and join the LESANZ community advancing best‑practice, impact‑driven commercialisation.
|
Join UniQuest’s commercialisation team as they share their insights and lessons
from the landmark acquisition of Vicebio - a company formed to develop UQ’s
Molecular Clamp technology, by global healthcare leader Sanofi.
The session will walk attendees through the key decisions, challenges and strategic
approaches that shaped the largest deal involving a company commercialising
Australian university IP.
The speakers will share their perspectives on structuring the agreement, navigating
complex negotiations, building strong researcher partnerships and the importance of
demonstrating meaningful impact.
Hosted with LESANZ, this session supports our mission to share best practice and
strengthen Australia’s commercialisation community. Attendees will gain practical
insights from the UniQuest team involved in the deal and connect with peers
committed to effective IPdriven innovation and commercialisation.
|
Event details: Thursday 5th March 2026
Venue:
The Precinct,
Launch Event Space
Level 3/315 Brunswick St,
Fortitude Valley QLD 4006
Time:
5:30pm arrival | 6:00–7:00pm presentation | Networking light refreshments afterwards
Seminar Pricing
$25 LESANZ member
$45 non-member
|
|
The speakers
|
Dr Dean Moss
Chief Executive Officer, UniQuest
Dr Craig Belcher
Head of Life Sciences, UniQuest
Jane Malloch
General Counsel, UniQuest
Dr Tamsin Terry
Senior Director, UniQuest
Nicole Cowan
Head of Marketing & Communications, UniQuest
|
|
Registration
Registration is closed. Contact the Secretariat for late registration